



Perma Fix Medical S.A Ranked Fifth Most Popular NewConnect Listed Investment Choice of Polish Fund Managers

Atlanta and Warsaw, Poland - June 16, 2015 -- Perma-Fix Medical S.A (WAR:PFM), a subsidiary of Perma-Fix Environmental Services, Inc., a NASDAQ listed company, today announced that its shares were ranked the fifth most popular NewConnect listed investment by Polish fund managers. At the end of December 2014, the market value of Perma-Fix Medical's shares held by investment funds amounted to approximately 7.5 million PLN (USD \$2.1 M). That constituted the fifth largest investment of asset managers managing mutual funds in NewConnect listed companies. The shares were allocated to the portfolios of two investment funds, managed by one of the largest mutual fund management companies in Poland (with assets under management in excess of USD \$5 billion). The ranking was prepared by Anality Online, one of the leading financial news agencies and providers of capital market research, based on the 2014 year-end financial statements of investment funds.

Steven Belcher, Chief Executive Officer of Perma-Fix Medical, stated, "We appreciate the continued support in our efforts to develop a safer and more cost-effective approach to solve worldwide shortages of medical isotopes and the confidence in our business model we received from Polish fund managers. The capital raised enabled us to validate the technology at two leading nuclear institutions in Europe and North America and perform the tests confirming that the proprietary resins could withstand higher levels of radiation, up to 4 curies, while producing clinically useful doses of Tc-99m. Our near term plans include additional demonstrations of our technology at even higher curie levels to commence full commercial scale-up of our process to produce Technetium-99m (Tc-99m) from Molybdenum-99 (Mo-99) without the use of uranium. We are also moving forward with formalization of additional partnerships and preparation for regulatory submissions in Europe and the U.S. With our plans to transition to the Main Market of the Warsaw Stock Exchange, we believe we will further increase our awareness and expand the number of potential institutional investors in the company."

About Perma-Fix Medical

Perma-Fix Medical is a subsidiary of Perma-Fix Environmental Services Inc., a NASDAQ listed company. It was formed to develop, obtain FDA and other regulatory approval and commercialize a new process to produce Technetium-99 (Tc-99m), the most widely used medical isotope in the world. The new process is expected to solve worldwide shortages of Tc-99m as it is less expensive, does not require the use of government-subsidized, weapons-grade materials and can be easily deployed around the world using standard research and commercial reactors, thereby eliminating the need for special purpose reactors. Please visit us on the World Wide Web at <http://www.medical-isotope.com>.

Contacts:

David Waldman or Justyna Gudaszevska
Crescendo Communications Europe Sp. z.o.o
Email: pfm@crescendo-ir.com
Tel: (+48 71) 79 11 551

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Perma-Fix's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Perma-Fix's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Perma-Fix's periodic filings with the Securities and Exchange Commission. The forward looking-statements in this press release are based upon management's reasonable belief as of the date hereof. Perma-Fix undertakes no obligation to revise or update publicly any forward-looking statements for any reason.